Does cabazitaxel have targeted potential in late stage prostate cancer?

A research team working just down the street here in Philadelphia thinks cabazitaxel (Jevtana) may have expanded potential in treatment of some men with castration-resistant prostate cancer (CRPC). … READ MORE …

TARP trial shows limited benefits from 5-ARI + an anti-androgen in CRPC

For some 15+ years there have been subsets of patients and physicians who have believed strongly that adding a 5α-reductase inhibitor (5-ARI) like finasteride or dutasteride to an anti-androgen would quite certainly aid in the prevention of prostate cancer progression because such a regimen would reduce levels of dihydrotestosterone. … READ MORE …

Low-dose diethystilbestrol in treatment of men with CRPC

It has been a long time since we saw any truly new data on the efficacy and safety of a very old form of hormonal therapy (diethylstilbestrol or DES) in the treatment of advanced prostate cancer. … READ MORE …

Innocrin Pharmaceuticals moving VT-464 into Phase II portion of Phase I/II trial

Innocrin Pharmaceuticals has been conducting the Phase I portion of a Phase I /II trial of VT-464, a CYP17 lyase inhibitor, in men with treatment-naïve CRPC and in CRPC patients who have failed prior therapy with abiraterone, enzalutamide, and/or chemotherapy. … READ MORE …

Who’s actually dying of prostate cancer (in France) today?

A newly published paper from a French research group has provided some interesting data on which patients actually die of prostate cancer in the modern, post-PSA era. … READ MORE …

Can galeterone show effectiveness in men with AR-V7 mCRPC?

According to a report in The ASCO Post last night, the investigational drug galeterone may have significant clinical activity against a specific subtype of castration-resistant prostate cancer (CRPC) known as AR-V7. … READ MORE …

Bayer, Orion initiate Phase III trial of ODM-201 in non-metastatic CRPC

According to a media release today from Bayer HealthCare and Orion Corporation (a Finnish pharmaceutical company), they have started to  enroll patients in a randomized Phase III clinical trial of ODM-201, a novel, oral androgen receptor inhibitor in development for the treatment of men with advanced forms of prostate cancer. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,351 other followers